11. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020 Mar 11:e13298. doi: 10.1111/dth.13298.
12. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020 Mar 18. pii:S0190-9622(20)30445-X. doi: 10.1016/j.jaad.2020.03.031
13. Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. ArXiv200300751 Q-Bio [Internet]. 2020 Mar 2 (Accessed 2020 Mar 21); Available from: http://arxiv.org/abs/2003.00751
14. ALK is a therapeutic target for lethal sepsis | Science Translational Medicine [Internet]. (Accessed 2020 Mar 21). Available from: https://stm.sciencemag. org/content/9/412/eaan5689.abstract
15. Wang M, Sooreshjani MA, Mikek C, Opoku-Temeng C, Sintim HO. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels. Future Med Chem. 2018 01;10(11):1301–17.
16. COVID-19 Registered Trials and analysis. CEBM. (Accessed 2020 Mar 29). Available from: https://www.cebm.net/covid-19/registered-trials-and-analysis/
17. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Mar [cited 2020 Mar 20]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.03.01.20029769
18. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 Apr 29.
19. EUSA Pharma initiates study of siltuximab to treat Covid-19 patients [Internet]. [cited 2020 Mar 21]. Available from: https://www.clinicaltrialsarena. com/news/eusa-pharma-siltuximab-study-covid-19/
12. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020 Mar 18. pii:S0190-9622(20)30445-X. doi: 10.1016/j.jaad.2020.03.031
13. Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. ArXiv200300751 Q-Bio [Internet]. 2020 Mar 2 (Accessed 2020 Mar 21); Available from: http://arxiv.org/abs/2003.00751
14. ALK is a therapeutic target for lethal sepsis | Science Translational Medicine [Internet]. (Accessed 2020 Mar 21). Available from: https://stm.sciencemag. org/content/9/412/eaan5689.abstract
15. Wang M, Sooreshjani MA, Mikek C, Opoku-Temeng C, Sintim HO. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels. Future Med Chem. 2018 01;10(11):1301–17.
16. COVID-19 Registered Trials and analysis. CEBM. (Accessed 2020 Mar 29). Available from: https://www.cebm.net/covid-19/registered-trials-and-analysis/
17. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Mar [cited 2020 Mar 20]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.03.01.20029769
18. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 Apr 29.
19. EUSA Pharma initiates study of siltuximab to treat Covid-19 patients [Internet]. [cited 2020 Mar 21]. Available from: https://www.clinicaltrialsarena. com/news/eusa-pharma-siltuximab-study-covid-19/
AUTHOR CORRESPONDENCE
Mohamad Goldust MD mohamad.goldust@usb.ch